Johnson & Johnson (JNJ)

The vaccine rollout has been bungled and the nation's in crisis, but you can either dwell on the negativity or look to ingenuity and opportunity. Here's where I see the latter.

If all goes well, JNJ could be able to immunize a billion individuals this year just by themselves.

A correction in EBS could soon set up an attractive opportunity.

This Friday several banks begin the unofficial kickoff of 'earnings season'.

As we move through Georgia and see an end in sight to Covid, we need a gut check on what stocks are really going to go the distance.

I am talking about themes that can stand the test not of today, or tomorrow, but for all of 2021 and beyond.

We have to take both the private sector and the states out of the equation, and adopt the process that wiped out Polio.

This is the time and the place to go long JNJ.

While there are certainly some things to like about AZN, I don't think this vaccine, nor the UK emergency authorization, make it investable.

I think BA returns to normal as we do, as the airlines do... but with the defense contracting business as a foundation to rely upon.

The Russell 2000 is now up 7% for December, twice the increase for the Nasdaq Composite.

We have bets coming from all directions, and holiday joy abounds as the wagerers move up their stocks with their buying. Let's see how this could play out.

I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.

Vaccines are on the move (a big plus) even as members of Congress continue to dawdle on a fiscal support package (a big minus).

Plus, stay nimble as the road just ahead could become a bit more treacherous than many may think.

The sooner that we get jabbed the more likely the economy can spring back to life.

This company has not only paid but increased its dividend for 58 consecutive years.

A weak dollar could provide a substantial tailwind for these companies.

The battle to gain control over Covid-19 is entering a crucial stage and calls for continued determination.

A look at the charts of Advanced Micro Devices and Tesla, plus a review of the 'broadening' market action from Thursday.

One of the most-hated sectors of the market is taking off, and it's not too late to get on board.

What happens when everyone hunkers down, creating their own de facto stay-in-place lockdown?

Monday's action in Johnson & Johnson is a fadeable event.

Portfolio managers are starting to see a very strong 2021 for markets and the economy regardless of electoral results.

Markets have certainly recovered nicely off of the lows of late September. Now, here in mid-October, it feels like it did that cold night back in 1980-something. The wolves are visible and noisy.

Investors are chasing every name that's developing a promising coronavirus vaccine. These stocks will be winners no matter which companies are successful.

Covid itself, and therapeutics or vaccines associated with taking on the SARS-CoV-2 coronavirus, is under a public microscope.

Market participants ignore negative news and continue to pursue individual stocks into earnings season.